Ann: Bod Australia investor evening, page-3

Good to see the company being proactive with their disclosure and management being available to live Q&A sessions. There's much to like about this announcement and its hinting at the potential Chinese market.
I 'd like to see the conditions targeted by their coming clinical study a bit more defined but it's notable that there's no formulation yet for the compound about to be tested. With a growing body of scientific literature on the workings of CBD, the focus should be on tackling symptoms which would be more effectively eased by the administering of the CBD via their sublingual WaferiX - for which iX Biopharma has secured patent protection in China.